A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG

Paul J van Diest, Peter van Dam, Sonja C Henzen-Logmans, Els Berns, Maria E L van der Burg, John Green, Ignace Vergote

Immunohistochemistry has become an important tool in surgical pathology, especially in the diagnosis of tumours. The demonstration of antigens more or less specific for different types of tumours has dramatically improved diagnostic accuracy. As well as being diagnostically important, the expression of several antigens, as demonstrated by immunohistochemistry correlates with the prognosis of some cancers. Examples are steroid receptors in breast and gynaecological cancers,1 oncogene products such as HER-2/neu in breast cancer,2 apoptosis related gene products such as bcl-2 in breast cancer,3 and cell cycle regulation proteins such as p53 (unpublished data), pRb,4 and cyclin D1 in breast, and head and neck cancer.5,6

However, the initial promising results of studies on these markers could not always be confirmed. This may be because of different methodological problems. First, there may have been selection of patients and differences in treatment. Second, there are often differences in tissue processing from study to study, especially with regard to the type of antibody and the application of antigen retrieval. Third, and possibly most important, interpretation of staining and presentation of the results are not standardised resulting in low intraobserver and interobserver reproducibility. These problems are a very important obstruction for possible clinical applications. There is therefore a clear need for consensus on a protocol for scoring of immunohistochemical staining.

The aim of this article is to discuss the most important items that should be part of a protocol for the scoring of immunohistochemical staining (staining patterns, tumour area to be assessed, sampling of fields of vision, scoring method, decision thresholds) and to suggest some solutions for common problems to reach a more standardised interpretation and presentation of immunohistochemical staining results. Scoring of immunocytochemical staining will not specifically be addressed, although many of the issues discussed will be applicable to cytological material.

Tissue processing
There are several steps in tissue processing that may influence staining patterns and intensity. These include type and duration of fixation, section thickness, antigen retrieval procedures, type and concentrations of primary, second (and third) step antibodies, and way of staining development—for example, it has recently been reported that tumour marker immunostaining intensity may be lost on stored paraffin wax slides of breast cancer.6,7 It is beyond the scope of this article to give an in depth overview of these factors, but these variables should be standardised as much as possible. Technically inadequate slides (uneven staining, uneven section thickness, heavy background) should be discarded.

Staining patterns
To arrive at reproducible interpretation, there must be agreement on the significance of nuclear, diffuse cytoplasmic or membrane staining for each specific antibody. Most antigens either localise (functionally) in the nucleus (such as pRb, p53, cyclin D1, steroid receptors), in the cytoplasm (Bax) or in the cellular membrane (HER-2/neu). Staining patterns other than the typical pattern for a given antibody (for example, cytoplasmic rather than nuclear staining for steroid receptors, or diffuse cytoplasmic instead of membrane staining for HER-2/neu) may have to be regarded as unfocal and ignored, although for some antigens it will be useful to record these seemingly aberrant expression patterns until their biological role and clinical significance are better understood.8

Area to be assessed
Although a purely random approach may sometimes be optimal, it will for most applications be necessary to define in which part of the lesion the staining will be assessed. For instance, invasive areas may be chosen over in situ parts, for proliferation markers the periphery of tumours is preferred. For prognostic applications, often the most poorly differentiated area of the tumour will be selected as this yields best clinical correlations, but for
diagnostic applications the best differentiated areas are usually most useful because typical antigen patterns are best preserved. The tumour area to be selected should be clearly defined for each marker, and guidelines for the (minimal) size of this area (to be marked on the slide for future reference) must be given.

**Sampling of fields of vision**

Within the marked tumour area, it will usually neither be possible (considering the workload involved) nor necessary to assess all available fields of vision. Therefore, some form of sampling will have to be applied. It is a matter of experience\(^1\)\(^2\) that this should not be left to the convenience of the observer as this will lead to interobserver variation and lack of reproducibility. Since some degree of clustering is usually present, the best way of sampling fields of vision is usually by systematically spreading them over the whole chosen tumour area (fig 1). This makes sure that cells over the whole chosen area are assessed and will lead to the most representative sample and highest reproducibility.\(^1\)\(^2\)

**Assessment of positivity of immunohistochemical staining**

**QUALITATIVE ASSESSMENT**

Qualitative assessment of immunohistochemical staining is widely used to judge visually whether any positivity of staining (compared with the background) is present in the cells under study. This way of assessing positivity is often the usual practice for diagnostic reasons and is quite satisfactory for stains where the mere presence of antigens is informative irrespective of the degree of positivity or the fraction of positive cells, such as for keratins and CD31.

**QUANTITATIVE ASSESSMENT**

For certain antigens, especially those predictive of response to treatment or related to prognosis such as p53, cyclin D1, steroid receptors, cathepsin D, and multidrug resistance related proteins, one needs to know the degree of positivity and the fraction of positive cells. A more sophisticated scoring procedure than qualitative assessment is needed. Such staining has semiquantitatively been scored as: \(\rightarrow\) (negative), + (positive), ++ (strongly positive), or +++ (very strongly positive). Although this approach may be very intuitive, problems arise when there is heterogeneity in staining—for example, it is usually not clear what to do with heavy staining in just a small number of cells. Some have advocated to report the staining intensity and the percentage of positive cells. An even more refined method is the Histo-score,\(^3\)\(^4\) where the fractions of negative (score 0), weakly positive (score 1), positive (score 2), strongly positive (score 3), and very strongly positive (score 4) cells are estimated, the fractions are multiplied with the scores and summed, the total being the H-score. This method is widely applied to score steroid receptor positivity in breast cancer. However, in practice, the fractions are only roughly estimated without counting, and assigning a score to an individual nucleus is highly subjective. Studies have shown that the scoring of no staining (score 0) and very strong staining (score 4) is quite reproducible, but that there are many interobserver discrepancies in scores 1–3.\(^4\) Therefore, this method is not optimal.

Alternatively, image analysis has been applied. Theoretically, image analysis allows the assessment of the amount of staining per cell by measuring absorption. However, in practice, immunohistochemistry using diaminobenzidine (DAB) as chromogen appeared to be only stoichiometric (linear relation between the amount of antigen and staining intensity as measured by degree of absorption) at low levels of intensity and not at the usual intensities used in daily immunohistochemistry.\(^5\) This approach has therefore lost some of its initial popularity. Using the alkaline phosphatase antialkaline phosphatase (APAAP) approach or antibodies directly labelled with a fluorescent dye seems more promising, but more experience is needed. Nevertheless, image analysis may well serve to assess objectively the number of positive cells,\(^6\)\(^7\) although it remains a rather labourious and relatively expensive procedure.

Recently, an interactive approach for immunoscopying has been developed based on stereology,\(^4\)\(^8\)\(^–\)\(^10\) which is very quick, simple, and reproducible. In a defined area of the lesion, fields of vision systematically spread over the whole area of interest are chosen, as illustrated in fig 1. As the first field is chosen at random, all fields are random, so this way of sampling is called systematic at random. This can be done manually, but is most efficiently done by means of a software guided automatic scanning stage. In these fields of vision, cells are selected using a point grid, and the positivity of these cells is scored. The principle here is to sample relatively few cells from relatively many fields of vision, or the "do more less well" principle.\(^2\)\(^11\) The number of fields of vision and cells to be assessed will vary from application to application and is
Consensus on scoring for immunohistochemical staining

dependent on the desired accuracy. In practice, 200 cells sampled from 50–100 fields of vision will allow a coefficient of variation < 5%. However, on occasion (for example, in case of values very close to the decision threshold) one may have to count more cells to reach an even higher accuracy. In general, it is not necessary to count 1000 cells as has been suggested. As fields spread over the whole area of interest are assessed (which copes best with clustering that is often observed) and selection of cells is unbiased, this approach leads to the highest reproducibility. Good clinical correlations with this method have been found in Barrett's oesophagus, breast cancer, and lymphomas.

This approach is especially useful to assess the percentage of positive cells irrespective of the staining intensity, but obviously does not overcome the problems involved in the subjective assessment of degree of positivity as previously mentioned.

Choice of cut off points

After having assessed the percentage of positive cells, the question is obviously how to choose the cut off value for decision making on "positivity". To this end, different approaches may be followed. First, staining percentages may be compared with biochemical findings. Second, a cut off point may be tuned to molecular biological results—for example, presence of DNA amplification or the amount of mRNA. Third, one may derive a cut off point from clinical studies taking clinical end points such as recurrence or survival, or response to a certain treatment. Preferably, such clinical cut off points should be established in a learning set of patients and confirmed in an independent patient group. Also, cut off points should be standardised from one study to another. This is essential for semiquantitative scoring.

Reporting

Results of immunoquantitation should preferably not just be reported as positive or negative, but the quantification method should be provided as well as exact data from the quantitation and the decision threshold. This can be done by merely providing the data, but graphically presenting the data may be more illuminating and easy to understand.

Summary of suggested protocol

In summary, when you are interested not just in mere presence of antigen but the fraction of positive cells is of interest irrespective of the staining intensity, we suggest an interactive stereological approach in a carefully defined part of the lesion. This consists of a systematic random sampling of fields of vision, preferentially guided by an automatic scanning stage, and assessment of positivity of cells in these fields selected with a point grid. Technically adequate slides are a prerequisite. An example of a protocol for such an approach is presented below:

- Define the area of interest.
- Define the area of the lesion to be assessed (periphery v central parts), relevant tissue parts (in situ v invasive), and cells of interest
- In this area, apply a systematic random sampling approach for selection of a defined number of fields of vision
- In the fields of vision, assess positivity of cells selecting 1000 cells as has been suggested
- Define the number of cells to be assessed, using the principle that few cells should be sampled from many fields of vision (for example, 2–4 cells from 50–100 fields of vision yielding a total of 200 counts)
- Define cut off value
- Define how the results should be reported. Such methods are fast, simple and highly reproducible. Application of such protocols will yield more objective data on the distribution of antigens in different lesions, which will be easier to compare from study to study, and will speed the process towards clinically applicable tests.

We thank Dr Gerrit A Meijer, and Professor Jan P A Baak, department of pathology, Free University Hospital, Amsterdam, the Netherlands, for their comments on the text and earlier contributions to the development of the protocols for immunohistochemical staining. Dr R Verheijen, department of pathology, Free University Hospital, Amsterdam, The Netherlands, and Dr Ivana Tedrovic, EORTC, are thanked for critically reading the text.

4. Withdrawn.


20 Polkowski W, Baak JPA, Lanschot JJB van, Meijer GA, Schuurmans LT, Kate FJW ten, et al. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation. J Pathol. [In press.]


A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG.
European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group.

P J van Diest, P van Dam, S C Henzen-Logmans, E Berns, M E van der Burg, J Green and I Vergote

*J Clin Pathol* 1997 50: 801-804
doi: 10.1136/jcp.50.10.801

Updated information and services can be found at:
http://jcp.bmj.com/content/50/10/801.citation

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/